The potential application of glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide, GIP) in the management of obesity and type 2 diabetes has been controversial. Initial interest in the therapeutic use of GIP was dampened by evidence that its insulinotropic activity was reduced in type 2 diabetes and by reports that it increased glucagon secretion and adipose deposition in non-diabetic individuals.
Lyophilized from a 0.22 µm filtered solution of PBS, pH 7.4.
Target:
GIP
Application Dilute:
Lyophilized from a 0.22 µm filtered solution of PBS, pH 7.4.
Application Notes:
Cross-Reactivity: Centrifµge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage,it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA,5% HSA,10% FBS or 5% Trehalose),and aliquot the reconstituted protein solution to minimize free-thaw cycles., ResearchArea: Other Recombinant Protein
Recombinant Human Gastric inhibitory polypeptide/GIP Protein was determined by SDS-PAGE under reducing conditions with Coomassie Blue.
* VAT and and shipping costs not included. Errors and price changes excepted
